Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immuno-guided versus viremia-guided CMV prevention after kidney transplantation
2011-005708-13Phase 4Terminated
- Sponsor
- Fundación para la Investigación Biomédica del Hospital 12 de Octubre
- Start
- May 2013
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of valganciclovir and ganciclovir in cytomegalovirus disease (CMV) (2 arms), sponsored by Fundación para la Investigación Biomédica del Hospital 12 de Octubre. Primary endpoint: Incidence of CMV disease during the first 6 months post-transplant. Started May 2013; status: terminated.
02
Drugs
valganciclovirganciclovir
03
Conditions
cytomegalovirus disease (CMV)
Beyond the preview
Go deeper on 2011-005708-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-005708-13.